NCM
TYRA icon

Nantahala Capital Management’s Tyra Biosciences TYRA Stock Holding History

Nantahala Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$1.39M – 159
2024
Q4 		$1.39M Buy
+100,000
New +$1.81M 0.06% 116

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Nantahala Capital Management's TYRA Position: Q1 2025 in Review

Nantahala Capital Management sold out of Tyra Biosciences (TYRA) in Q1 2025, closing a stake of 100,000 shares — an estimated $1.39M sold.

Nantahala Capital Management first reported a position in TYRA in Q4 2024 and held it in 1 quarter. The position peaked at $1.39M in Q4 2024. 117 funds tracked by Wall St. Rank hold TYRA as of Q1 2025.

  • Nantahala Capital Management reported no remaining Tyra Biosciences position as of Q1 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 100,000 Tyra Biosciences shares in Q1 2025, an estimated $1.39M.
  • Nantahala Capital Management first reported a position in Tyra Biosciences in Q4 2024 and held it in 1 quarter.
  • Nantahala Capital Management's Tyra Biosciences position peaked at $1.39M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2025.

Based on Nantahala Capital Management's 13F filing for Q1 2025, filed 15 May 2025.